Jupiter Neurosciences, Inc. Common Stock

Jupiter Neurosciences (NASDAQ: JUNS), a clinical-stage biopharmaceutical company focused on CNS disorders and neuroinflammation, announced a registered direct offering of 7,142,858 shares of common stock for approximately $2.0 million gross proceeds. The offering is expected to close on May 21, 2026, with D. Boral Capital LLC serving as the exclu...

Jupiter Neurosciences (NASDAQ: JUNS) announced a webinar on January 6, 2026, where CEO Chister Rosén will discuss the company's JOTROL™ resveratrol platform, upcoming Phase 2a Parkinson's disease trial, and commercialization of its Nugevia™ consumer product line. The company is pursuing a dual-path strategy combining pharmaceutical developme...

Jupiter Neurosciences announced a significant advancement in resveratrol technology with JOTROL™, achieving nine-fold increased bioavailability and reduced gastrointestinal side effects, with potential applications in neurodegenerative disease treatment and consumer supplements.

Jupiter Neurosciences announced the launch of Nugevia, a new consumer longevity supplement line powered by its patented JOTROL delivery platform. The company has partnered with professional golfer Annika Sörenstam as the brand ambassador for Nugevia.

Jupiter Neurosciences, a clinical-stage pharmaceutical company, has announced the closing of its $11 million initial public offering. The company plans to use the proceeds to fund a Phase II clinical trial for its product candidate JOTROL™ in Parkinson's Disease, as well as for other research and development activities.